ArticleCureus2026
Secretome-Assisted Regenerative Therapy for Hyaluronic Acid Filler-Induced Vascular Occlusion: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyaluronic acid (HA) fillers are widely used for non-surgical facial contouring, but vascular occlusion remains one of the most feared complications due to its potential to cause necrosis, functional impairment, and permanent deformities. Conventional management focuses on high-dose hyaluronidase and supportive therapy, which may not always prevent long-term sequelae. In recent years, regenerative approaches such as secretome and mesenchymal stem cell (MSC) therapies have emerged as promising alternatives. We report the case of a 29-year-old woman who developed nasal vascular occlusion following HA filler injection by a non-medical injector. Initial presentation included localized pain and cutaneous necrosis in the nasal tip. Early management involved repeated hyaluronidase infiltration, oral sildenafil, a single dose of prednisone, and adjuvant intravenous peroxidation therapy. Subsequently, 12 local applications of standardized MSC-derived secretome were administered. This strategy promoted granulation tissue formation, re-epithelialization, and partial recovery of skin integrity. However, clinical persistence of nasal asymmetry suggested cartilage involvement. To address this, an additional injection of 10 million MSCs was performed, leading to stable cutaneous coverage and improvement of nasal contour within 45 days. At the two-year follow-up, the patient showed a stable scar with mild hypopigmentation and surface irregularity. This case highlights the translational potential of regenerative therapies as an alternative to reconstructive surgery in filler-induced vascular complications. Secretome demonstrated efficacy in soft tissue repair, while MSCs contributed to structural restoration. Regenerative strategies may expand the therapeutic arsenal for HA filler-related vascular events, offering non-surgical and biologically targeted options for tissue preservation and functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.